AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12012144 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (60 mg) after high-fat American breakfast
Number of subjects: 24
Study 12012144 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (60 mg) under fasted conditions
Number of subjects: 24
Study 12012144 — intervention group
Group type: COMPARATOR
Intervention: Reference product (60 mg) after high-fat American breakfast
Number of subjects: 24
Study 12012144 — intervention group
Group type: COMPARATOR
Intervention: Reference product (60 mg) under fasted conditions
Number of subjects: 24
Study 10523801 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg/d oral clodronate
Number of subjects: 50
Study 10523801 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 mg/d oral clodronate
Number of subjects: 50
Study 10523801 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clodronate)
Number of subjects: 50
Study 7669316 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (start: 1%, maximum: 7%)
Number of subjects: 40
Study 7669316 — intervention group
Group type: COMPARATOR
Intervention: Halothane (start: 0.5%, maximum: 5%)
Number of subjects: 40
Study 2140330 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg twice daily for a maximum of 14 days
Number of subjects: 72
Study 2140330 — intervention group
Group type: COMPARATOR
Intervention: Josamycin 1000 mg twice daily for a maximum of 14 days
Number of subjects: 72
Study 7367177 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontalis EMG feedback
Number of subjects: 60
Study 7367177 — intervention group
Group type: COMPARATOR
Intervention: Non‐contingent feedback
Number of subjects: 60
Study 7367177 — intervention group
Group type: COMPARATOR
Intervention: Self-relaxation
Number of subjects: 60
Study 30883164 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier Reduction Intervention (BRI)
Number of subjects: 0
Study 30883164 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 0
Study 27565129 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage at 4 ± 2°C for up to 48 hr
Number of subjects: 102
Study 27565129 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage at 23 ± 2°C for up to 48 hr
Number of subjects: 102
Study 27565129 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage at 31 ± 2°C for up to 48 hr
Number of subjects: 102
Study 27565129 — intervention group
Group type: EXPERIMENTAL
Intervention: All temperatures (4 ± 2°C, 23 ± 2°C, 31 ± 2°C) for up to 48 hr
Number of subjects: 102
Study 26291953 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LF)
Number of subjects: 87
Study 26291953 — intervention group
Group type: COMPARATOR
Intervention: Open Nissen fundoplication (OF)
Number of subjects: 87
Study 23866988 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced on-site integrated care (ROIC)
Number of subjects: 125
Study 23866988 — intervention group
Group type: COMPARATOR
Intervention: Standard on-site integrated care (SOIC)
Number of subjects: 125
Study 21192153 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (36 mg/d to 108 mg/d)
Number of subjects: 550
Study 19038378 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing prompts based on cognitive restructuring techniques
Number of subjects: 38
Study 19038378 — intervention group
Group type: COMPARATOR
Intervention: Unstructured writing about a recent problematic social situation
Number of subjects: 38
Study 19038378 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater purposeful engagement ability
Number of subjects: 38
Study 17206296 — intervention group
Group type: EXPERIMENTAL
Intervention: Management at primary care level
Number of subjects: 201
Study 17206296 — intervention group
Group type: COMPARATOR
Intervention: Advanced age
Number of subjects: 201
Study 17206296 — intervention group
Group type: COMPARATOR
Intervention: Presence of diabetes
Number of subjects: 201
Study 15082950 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 90
Study 15082950 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 90
Study 15082950 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 90
Study 12423181 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex method (sets of half squats before sets of jump squats)
Number of subjects: 11
Study 12423181 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast method (alternation of sets of half squats and jump squats)
Number of subjects: 11
Study 12423181 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (sets of power exercises before sets of half squats)
Number of subjects: 11
Study 12669743 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate therapy
Number of subjects: 0
Study 12669743 — intervention group
Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 0
Study 7755380 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy with adreno-oophorectomy
Number of subjects: 371
Study 7755380 — intervention group
Group type: COMPARATOR
Intervention: Chemo-endocrine therapy with FAC
Number of subjects: 371
Study 1980201 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg suriclone
Number of subjects: 16
Study 1980201 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam (2 mg)
Number of subjects: 16
Study 1980201 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 1980201 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg suriclone
Number of subjects: 16
Study 6968611 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk laxative and a large anal dilator
Number of subjects: 40
Study 6968611 — intervention group
Group type: COMPARATOR
Intervention: Bulk laxative only
Number of subjects: 40
Study 31797035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI) - 5 minutes at 6 °C, excluding the head (n=9)
Number of subjects: 18
Study 31797035 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (CON) (n=9)
Number of subjects: 18
Study 30295731 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone pre-treatment for 2 months prior to LNG-IUS insertion
Number of subjects: 58
Study 30295731 — intervention group
Group type: COMPARATOR
Intervention: Comparator group (no mifepristone pre-treatment)
Number of subjects: 58
Study 27543440 — intervention group
Group type: EXPERIMENTAL
Intervention: Early coronary blood flow (CBF) to left ventricular (LV) systolic function ratios (stunning index)
Number of subjects: 24
Study 27543440 — intervention group
Group type: EXPERIMENTAL
Intervention: Early coronary blood flow (CBF) to left ventricular wall motion score index (LVMSI) ratios
Number of subjects: 24
Study 27543440 — intervention group
Group type: EXPERIMENTAL
Intervention: Early coronary blood flow (CBF) to left anterior descending wall motion score index (LADWMSI) ratios
Number of subjects: 24
Study 25295804 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 inhibitor (C1 INH‐nf; human) 1000 U intravenous injections every 3-4 days for 12 weeks
Number of subjects: 22
Study 25295804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 21477164 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (-110 ± 3 °C)
Number of subjects: 36
Study 21477164 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 ± 3 °C)
Number of subjects: 36
Study 19593157 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-Minute Walk Test
Number of subjects: 24
Study 19593157 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy age-matched and sex-matched individuals)
Number of subjects: 24
Study 19593157 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 24
Study 19593157 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 18538705 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile water
Number of subjects: 20
Study 18538705 — intervention group
Group type: COMPARATOR
Intervention: 0.05% CHG
Number of subjects: 20
Study 16032934 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA‐BDP 160 mcg twice daily
Number of subjects: 30
Study 16032934 — intervention group
Group type: COMPARATOR
Intervention: CFC‐FP 220 microg each morning and 110 microg each evening
Number of subjects: 30
Study 12455197 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (LAC)
Number of subjects: 333
Study 12455197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study 10653204 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam 1 mg and Sertraline 100 mg (CZ + SR)
Number of subjects: 13
Study 10653204 — intervention group
Group type: COMPARATOR
Intervention: Clonazepam 1 mg and Placebo (CZ + PL)
Number of subjects: 13
Study 8559528 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) tablets (3 mg)
Number of subjects: 95
Study 8559528 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (continuous intravenous drip)
Number of subjects: 95
Study 8559528 — intervention group
Group type: EXPERIMENTAL
Intervention: Atad Ripener Device
Number of subjects: 95
Study 1814144 — intervention group
Group type: EXPERIMENTAL
Intervention: Short words consisting of fricative consonant/vowel combinations
Number of subjects: 0
Study 1814144 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorization task with words
Number of subjects: 0
Study 1814144 — intervention group
Group type: EXPERIMENTAL
Intervention: Tone 'probes' presented randomly to either ear with speech sounds to one ear
Number of subjects: 0
Study 1814144 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual input from articulatory movements of the speaker
Number of subjects: 0
Study 6880563 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide (250 mg) administered once
Number of subjects: 130
Study 6880563 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated administrations of chlorpropamide (250 mg b.i.d. for 2 days)
Number of subjects: 130
Study 6880563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 6880563 — intervention group
Group type: EXPERIMENTAL
Intervention: Metergoline (antiserotonin agent) and bromocriptine (dopamine-agonist)
Number of subjects: 130
Study 31627309 — intervention group
Group type: EXPERIMENTAL
Intervention: ELASTEN® (collagen supplement)
Number of subjects: 72
Study 31627309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 29402908 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Reality (ER) analgesia, 5 times a week for 2 weeks
Number of subjects: 60
Study 29402908 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Reality (ER) analgesia, 5 times a week for 1 week
Number of subjects: 60
Study 27448328 — intervention group
Group type: EXPERIMENTAL
Intervention: Retigabine
Number of subjects: 15
Study 27448328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 25286167 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided telephone counselling for one year, supported by mailed newsletters
Number of subjects: 289
Study 25286167 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 289
Study 22192246 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin + metformin XR 1500 mg
Number of subjects: 282
Study 22192246 — intervention group
Group type: COMPARATOR
Intervention: uptitrated metformin XR 2000 mg
Number of subjects: 282
Study 20156668 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 20
Study 20156668 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 20
Study 17662012 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day
Number of subjects: 758
Study 17662012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 758
Study 16055373 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult visual task (digits 1-4)
Number of subjects: 0
Study 16055373 — intervention group
Group type: COMPARATOR
Intervention: Easy visual task (letters X)
Number of subjects: 0
Study 16055373 — intervention group
Group type: EXPERIMENTAL
Intervention: Nociceptive CO2 laser stimuli
Number of subjects: 0
Study 12325487 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 capsules of 100 mg APD
Number of subjects: 8
Study 12325487 — intervention group
Group type: COMPARATOR
Intervention: 2 tablets of 150 mg APD
Number of subjects: 8
Study 10404554 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cigarette consumption scenarios with varying nicotine concentrations
Number of subjects: 155
Study 10404554 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of cigarette consumption
Number of subjects: 155
Study 10404554 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents compared to adults
Number of subjects: 155
Study 10404554 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall perception of risk
Number of subjects: 155
Study 7584165 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and vitamin A supplementation
Number of subjects: 74
Study 7584165 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (no intervention)
Number of subjects: 74
Study 1439090 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol aerosol
Number of subjects: 10
Study 1439090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2883214 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg alpidem
Number of subjects: 10
Study 2883214 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg alpidem
Number of subjects: 10
Study 2883214 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg alpidem
Number of subjects: 10
Study 2883214 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg lorazepam
Number of subjects: 10
Study 2883214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29963684 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aminolaevulinic acid-photodynamic therapy with red light
Number of subjects: 0
Study 29963684 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aminolaevulinic acid-photodynamic therapy with green light
Number of subjects: 0
Study 27346343 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate protein-restricted (PR) diet
Number of subjects: 0
Study 27346343 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet specifically reduced in branched-chain amino acids (BCAAs)
Number of subjects: 0
Study 27346343 — intervention group
Group type: COMPARATOR
Intervention: PR diet
Number of subjects: 0
Study 26466857 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3
Number of subjects: 592
Study 26466857 — intervention group
Group type: COMPARATOR
Intervention: Clinical risk model without NT-proBNP
Number of subjects: 592
Study 26466857 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP and cTnI
Number of subjects: 592
Study 23387383 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation protocol (4-week duration)
Number of subjects: 64
Study 23387383 — intervention group
Group type: COMPARATOR
Intervention: Self-regulation guidebook only (comparison group)
Number of subjects: 64
Study 21684602 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 4425
Study 21684602 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 4425
Study 21684602 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwhite ethnicity
Number of subjects: 4425
Study 21684602 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperopia
Number of subjects: 4425
Study 21684602 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrum (Wyeth Consumer Healthcare, Madison, NJ) use
Number of subjects: 4425
Study 21684602 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 4425
Study 21684602 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher educational level
Number of subjects: 4425
Study 21684602 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 4425
Study 21684602 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy in female participants
Number of subjects: 4425
Study 18955427 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional group (n = 20) - active assisted range of motion exercises on the day of surgery, dynamic exercises for the rotator cuff after six weeks, strengthening exercises after eight weeks.
Number of subjects: 34
Study 18955427 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive group (n = 14) - active assisted range of motion and dynamic exercises for the rotator cuff on the day of surgery, strengthening exercises started after six weeks.
Number of subjects: 34
Study 18955427 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 34
Study 17151314 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and psychological adherence intervention (EP)
Number of subjects: 40
Study 17151314 — intervention group
Group type: COMPARATOR
Intervention: Exercise-only intervention (EO)
Number of subjects: 40
Study 12666466 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (kangaroo care)
Number of subjects: 146
Study 10704545 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-wavelength automated perimetry
Number of subjects: 25
Study 10704545 — intervention group
Group type: COMPARATOR
Intervention: Standard visual fields
Number of subjects: 25
Study 11825403 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal splenectomy with retroperitoneal transposition
Number of subjects: 72
Study 11825403 — intervention group
Group type: COMPARATOR
Intervention: Devascularization
Number of subjects: 72
Study 8172793 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOEP (4 cycles of cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone)
Number of subjects: 175
Study 8172793 — intervention group
Group type: COMPARATOR
Intervention: hCHOP/IVEP (4 cycles of dose-intensified CHOP alternating with ifosfamide, etoposide, vindesine, prednisolone)
Number of subjects: 175
Study 2963523 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol, 400 mg once daily
Number of subjects: 15
Study 2963523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 26439473 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy (MCT)
Number of subjects: 46
Study 26439473 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA)
Number of subjects: 46
Study 26439473 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control
Number of subjects: 46
Study 24564933 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)-based tight control strategy
Number of subjects: 0
Study 24564933 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 24564933 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d prednisone added to MTX-based tight control strategy
Number of subjects: 0
Study 24564933 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to MTX-based tight control strategy
Number of subjects: 0
Study 24564933 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control strategies (both MTX and prednisone)
Number of subjects: 0
Study 22616908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitafloxacin (STFX) 100 mg/day for 5 days
Number of subjects: 44
Study 22616908 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) under local anaesthesia
Number of subjects: 44
Study 22616908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitafloxacin (STFX)
Number of subjects: 44
Study 22616908 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 44
Study 20298418 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (250 microg twice daily)
Number of subjects: 70
Study 20298418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 19192868 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) treatments
Number of subjects: 0
Study 19192868 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience sampling method (ESM)
Number of subjects: 0
Study 15784033 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN monotherapy for 24 weeks (group A: long-term IFN therapy)
Number of subjects: 25
Study 15784033 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN monotherapy for 6 weeks (group B: short-term IFN therapy)
Number of subjects: 25
Study 15784033 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN monotherapy for 24 weeks (group A) among patients with HCV viral load <100 kIU/ml
Number of subjects: 25
Study 15784033 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN monotherapy for 6 weeks (group B) among patients with HCV viral load <100 kIU/ml
Number of subjects: 25
Study 12422252 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine without preservative (active drug)
Number of subjects: 2
Study 12422252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 12422252 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of dimenhydrinate (active drug)
Number of subjects: 2
Study 12422252 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four doses)
Number of subjects: 2
Study 12422252 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine (active drug)
Number of subjects: 2
Study 8537585 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST) using weight machines (n = 25)
Number of subjects: 105
Study 8537585 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET) using stationary cycles (n = 25)
Number of subjects: 105
Study 8537585 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Strength Training and Endurance Training (ST+ET) (n = 25)
Number of subjects: 105
Study 8537585 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30) with no intervention
Number of subjects: 105
Study 2816875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 100 mg/6 h
Number of subjects: 10
Study 2816875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg/4 h
Number of subjects: 10
Study 2816875 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg/6 h
Number of subjects: 10
Study 2816875 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg/4 h
Number of subjects: 10
Study 2816875 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ranitidine 0.2 mg/kg/h
Number of subjects: 10